A global research leader, the Alzheimer's Association is at the forefront of groundbreaking research advancing medical precision in the new era of treatments for Alzheimer's.

**PART THE CLOUD Gene Targeting Challenge**

funding initiative accelerating clinical trials for Alzheimer's and other dementia

Personalized medical approaches that address individual biological circumstances are the future of treatment for Alzheimer's.

The U.S. Food and Drug Administration approved two new treatments for Alzheimer's disease that target the abnormal accumulation of beta-amyloid "plaques," a hallmark brain change observed in Alzheimer's.

This targeted intervention in the human brain also leads to a reduction in disease-specific tau protein levels.

A number of factors and processes likely contribute to the development of brain diseases such as Alzheimer's disease, and these may not be the same for every individual.

Effective treatment is likely to be a combination therapy of two or more drugs targeting distinct biological processes.

Scientists have identified more than 100 risk genes associated with the development of Alzheimer's.

These risk genes may influence biological changes in the brain that differ from person to person, presenting opportunities for personalized gene editing and therapy.

Founded in 2012 by philanthropist Michaela "Mikey" Hoag, Part the Cloud propels Alzheimer's research by rallying visionary philanthropists to provide critical support for promising early-stage clinical trials.

- **65 global** projects
- **$68 million** since 2012
- **$1.4+ billion** follow-on-funding

**Part the Cloud drug pipeline**

- **25** experimental drugs advanced from preclinical trials to phase 1
- **9** drugs advanced from preclinical trials to phase 2
- **20** drugs advanced from phase 1 to phase 2
- **1** experimental drug advanced from preclinical trials to phase 3

alz.org/partthecloud
Grants will support new and ongoing early-stage clinical trials using gene targeting. Examples of similar Part the Cloud-funded trials of gene therapies include:

- Ross Paterson, MRCP, Ph.D., at University College London, who is conducting a phase 1b trial to test whether targeting specific genes can lead to the reduction of tau tangles, a hallmark of Alzheimer’s disease and many other neurodegenerative diseases.

- Mark Tuszynski, M.D., Ph.D., at University of California, San Diego, whose phase 1 gene therapy trial aims to improve the survival and function of brain cells in Alzheimer’s disease.

The stage is set for unprecedented acceleration of targeted genetic research for Alzheimer’s.

We seek visionary philanthropic partners to join with us by making a high-impact gift for this challenge. Together, we will make transformative progress toward our vision of a world without Alzheimer’s and all other dementia.

Learn more and make a donation at alz.org/partthecloud